Aravive Investor Presentation Deck

GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors and Expression Associated with Poor Survival in Many Cancers 1 The GAS6/AXL pathway mediates multiple steps of metastasis. AXL activation regulates downstream signaling, including the JAK/STAT pathway, Ras/MEK/Erk1/2 pathway, and PI3K/Akt pathway. The GAS6/AXL pathway upregulates pro- tumorigenic functions, such as immune evasion, survival, proliferation, drug resistance, angiogenesis, epithelial-to- mesenchymal transition (EMT), migration, and invasion. GAS6 and AXL are also expressed by stromal cells, including endothelial cells, pericytes, and subsets of immune cells, to promote tumor progression and metastasis. . . However, GAS6 is redundant for normal tissues and depletion does not cause abnormal phenotype 2 Natural Killer (NK) Cells T-Cells Dendritic Cells Macrophages Immune Evasion † Survival & Proliferation Endothelial cells Pericytes Actin 0-0-0- -0.0 Axl 1 Cell Death and Disease (2017) 8, e2700. 2 Nature 1999, 398, 723-728 „Twist, Soul Sky dopos Cardal Peripheral refo dynamica Drug t Angiogenesis EMT Resistance Adrive cyt Migration & Invasion Tanaka, M.; Siemann, D.W. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer. Int. J. M Sci 2021, 22, 9953 https://doi.org/10.3390/jms22189953 5 Ch

View entire presentation